Ryan Oneil Lomeda
Family · Dallas, TXNPI 1811541055
Payments from drug & device makers
Across 260 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Merck$485
- Novo Nordisk$319
- AbbVie$287
- EMD Serono, Inc.$223
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,050100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 54 | $1,608 |
| Viiv Healthcare Company | 79 | $1,493 |
| Merck | 13 | $485 |
| Novo Nordisk | 25 | $319 |
| AbbVie | 10 | $287 |
| EMD Serono, Inc. | 8 | $223 |
| Theratechnologies Inc. | 7 | $204 |
| Lilly USA, LLC | 10 | $165 |
| Johnson & Johnson(2 entities) | 6 | $144 |
| Amgen | 6 | $131 |
| Otsuka America Pharmaceutical, Inc. | 5 | $124 |
| AstraZeneca | 3 | $117 |
| Janssen Products, LP | 1 | $115 |
| Napo Pharmaceuticals Inc | 5 | $112 |
| Antares Pharma, Inc. | 5 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Pylant Medical | 2 | $66 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| GSK | 3 | $43 |
| Lundbeck LLC | 2 | $43 |
| Pfizer | 2 | $42 |
| Neos Therapeutics, LP | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,050 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 33 | $147,578 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 20 | $79,852 |
| DescovyEmtricitabine/Tenofov Alafenam | 28 | $61,566 |
| TivicayDolutegravir Sodium | 12 | $48,867 |
| Maraviroc | 16 | $28,837 |
| Etravirine | 24 | $25,967 |
| EdurantRilpivirine Hcl | 12 | $20,494 |
| Testosterone | 27 | $5,219 |
| Trazodone Hcl | 44 | $531 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $501 |
| Atorvastatin Calcium | 49 | $452 |
| Acyclovir | 12 | $321 |
| Bupropion XlBupropion Hcl | 11 | $310 |
| Gabapentin | 13 | $214 |
| Amlodipine Besylate | 22 | $185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,608 | $209,14561 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay | $1,493 | $128,71932 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $6912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Hayley McKessonDallas$165K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Richard OrnbergDallas$56K
- Ifeoma OkekeDallas$48K
- Natasha SimmonsDallas$38K
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.